Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Schueneman v. Arena Pharmaceuticals, Inc. et al
Case Number:
3:10-cv-01959
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Cooley LLP
- Donahue Fitzgerald
- Gibbs Law Group
- Girard Sharp
- Hulett Harper
- Kaplan Fox
- Kessler Topaz
- Lieff Cabraser
- MoginRubin
- Wolf Haldenstein
Companies
Sectors & Industries:
-
November 08, 2017
Arena Pharma, Investors Strike $24M Deal In Diet Drug Suit
Arena Pharmaceuticals Inc. has reached a $24 million cash-and-stock deal with a proposed class of investors to settle its seven-year battle in California federal court over allegations the company lied to shareholders that testing was going smoothly for its diet drug lorcaserin, which is sold under the trade name Belviq.
-
January 10, 2017
9th Circ. Won't Rehear Investor Suit Over Arena's Diet Drug
The Ninth Circuit on Tuesday denied Arena Pharmaceuticals' request for a full panel rehearing of its decision that revived a proposed class action alleging the company lied to shareholders that testing for its new diet drug was going smoothly.